Atabecestat - Janssen Pharmaceuticals

Drug Profile

Atabecestat - Janssen Pharmaceuticals

Alternative Names: JNJ-54861911

Latest Information Update: 15 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shionogi
  • Developer Janssen Research & Development
  • Class Amides; Antidementias; Small molecules; Thiazines
  • Mechanism of Action Amyloid precursor protein secretase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 04 Jun 2018 Chemical structure information added
  • 25 May 2018 Janssen Research & Development terminates a phase II/III trial in Alzheimer's disease (In the elderly, In adults) in USA, Australia, Belgium, Canada, Denmark, Finland, France, Germany, Italy, Japan, Mexico, the Netherlands, Spain, Sweden, Switzerland, and the United Kingdom (PO) due to high elevations of liver enzymes in patients placing them at increased risk for severe liver injury
  • 25 May 2018 Janssen suspends patient enrolment in the phase II/III DIAN-TU trial for Alzheimer's disease (Early-stage disease) in USA, United Kingdom, Spain and Italy to explore options to improve the benefit / risk for these patients (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top